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ABSTRACT
Objective: The role of computed tomography perfusion (CTP) in characterizing primary prostate cancer 
(PCa) is not definitely known. The aim of the present study was to investigate the relationship between CTP 
parameters and histopathological features of PCa tissue, using a sector-wise approach.
Material and methods: Fifty-one patients with biopsy-proven PCa underwent prospectively a CTP scan 
prior to radical prostatectomy. Blood flow (BF), mean blood volume (BV) and mean transit time (MTT) 
were calculated, with the prostate being divided into eight sectors. Corresponding sector-wise histopatho-
logical analysis of whole-mount prostatectomy specimens was performed to determine tumoral area (mm2), 
mean microvessel density (MVD), Gleason patterns (primary, secondary) and total Gleason score. Spear-
man’s rank correlation coefficient was used to analyze the association between CTP and histopathological 
parameters. 
Results: BF correlated weakly with tumoral area [ρs coefficient (p-value): 0.25 (0.00)] and MVD [ρs coef-
ficient (p-value): 0.23 (0.00)]. No valuable correlation was found between CTP parameters and primary and 
secondary Gleason patterns, whereas total Gleason score was weakly correlated with BV [ρs coefficient 
(p-value): 0.22 (0.00)] and MTT [ρs coefficient (p-value): 0.25 (0.00)].
Conclusion: BF correlates weakly with size and vascularity of PCa. There is a need for further studies to 
elucidate the association between CTP parameters and other histopathological parameters.
Keywords: Computed tomography; Gleason score; multimodal imaging; perfusion imaging; prostate can-
cer.
Introduction
The technique of computed tomography perfu-
sion (CTP) imaging in oncology is based on 
the effects of tumoral angiogenesis.[1] Tumor 
vessels increase permeability and blood vol-
ume of the tissue, resulting in different patterns 
of contrast enhancement of viable tumor tissue 
in CT, as opposed to healthy tissue.[2] The com-
bination of such functional parameters with 
morphological imaging has shown benefits for 
noninvasive characterization of several tumor 
types, tumor staging and assessment of therapy 
response.[3,4] 
Although evidence-based guidelines and pro-
spective clinical trials are currently lacking, 
multiparametric magnetic resonance imag-
ing (MRI), using a combination of high-res-
olution T2-weighted images and at least two 
functional MRI techniques, is today the rec-
ommended technique for the noninvasive di-
agnosis and local staging of prostate cancer 
(PCa).[5] Given the increasing availability of 
MRI, CTP may represent a diagnostic chance 
for a minority of patients with contraindica-
tions to MRI, such as cases with implanted 
cardiac devices, or institutions not equipped 
with MR scanners.
The role of CTP in PCa is not well understood today, and only a 
few studies are currently available. CTP of the prostate had long 
time been hampered by technical difficulties which have been 
mostly overcome by recent advances in CT technique.[6] CTP 
analysis of the prostate is a robust technique, CTP parameters of 
the prostate are not influenced by tracer kinetics model used and 
colour-coded CTP maps reduce the risk of inter-observer dif-
ferences.[7,8] Unlike MR perfusion, which relies on a change of 
signal intensities, the concept of CTP is based on tissue density 
and thus allows for a direct quantification. However, CTP study 
results obtained in PCa patients are partially discrepant, prob-
ably owing to the zonal architecture of the prostate and frequent 
coexistence of several diseases, such as benign prostatic hyper-
plasia (BPH), fibrosis, and prostatitis, as well as the ambigious 
nature of PCa itself (multifocal, microfocal, diffusely infiltrating 
etc.). A comparison between in vivo CTP parameters and histo-
pathological markers of PCa angiogenesis has been performed 
only in a limited number of studies.[9,10] 
Recently, CTP using an en-bloc approach has demonstrated 
that perfusion parameters may predict the aggressiveness of 
PCa more precisely than histopathological findings of biopsy 
specimens.[11] However, any correlation between perfusion pa-
rameters and Gleason score could not be demonstrated, which 
is usually present between Gleason score, and MRI perfusion 
findings.[12,13] The aim of our study was to investigate the rela-
tionship between CTP parameters and histopathological features 
of PCa tissue using a comprehensive, sector-wise approach.
Material and methods
Patient population
A cohort of ninety-eight consecutive male patients (median 
age 67 years, range 49 to 84) underwent a CTP scan. This 
prospective study was approved by the institutional review 
board and performed in accordance with the ethical standards 
laid down in the Declaration of Helsinki Ethical Principles 
for Medical Research Involving Human Subjects. Informed 
consent was obtained from all individual participants includ-
ed in the study.
Inclusion criteria were: biopsy-proven PCa within the last 8 
months, referral for initial staging examination by abdominal 
CT and/or bone scan, willingness to undergo an additional CT 
scan in order to acquire CTP image datasets, and scheduled start 
of therapy in less than 6 months. All patients were comprehen-
sively assessed with a thorough medical history, and complete 
clinical and demographic data were collected, including serum 
concentrations of prostate-specific antigen (PSA). Exclusion cri-
teria were: renal insufficiency (defined as renal clearance <30 
mL/min); allergy or hypersensitivity to iodinated contrast me-
dium, and untreated hyperthyroidism. 
Fifteen patients were excluded after the scan for various reasons 
such as power injector malfunction (n=7), movement artifacts 
(n=1), beam hardening artifacts due to hip prosthesis (n=5), 
metal markers within the prostate (n=2), and presence of dis-
seminated bone metastases (n=3). The remaining eighty patients 
with localized PCa subsequently underwent radical prostatec-
tomy (RP). While 29 patients were subsequently excluded from 
the study because they did notundergo RP within the defined pe-
riod of 150 days. Whole-mount histopathological analysis was 
performed in all prostatectomy specimens of the 51 evaluable 
patients. 
Integrated CT-perfusion protocol
All CT scan were performed with a Somatom Definition Flash® 
scanner (Siemens Healthcare, Erlangen, Germany). The covered 
scan length was 7 cm. The scanning time was 60 s, rotation time 
1 s; tube current 100 mAs and tube voltage 100 kV(p). Slice 
width was 5 mm with reconstruction increment of 3 mm. CT-
perfusion scanning started with a delay of 10 s after the injection 
of 40 mL of iodinated contrast medium (Iopromidum 769 mg/
mL, Ultravist® 370, Bayer Healthcare, Leverkusen, Germany) 
at an infusion rate of 4.5 mL/s. 
If the patient had been referred for a staging CT, a CT scan of the 
abdomen was acquired subsequently after injection of another 
60 ml of contrast medium and after a delay of 40 s (tube volt-
age 120 kV(p), quality reference tube current 210 mAs, pixel 
matrix 512x512, reconstructed slice thickness 2 mm, increment 
1.5 mm). 
Two radiologists (M.H., P.V.H.) performed all image analysis 
in consensus. Perfusion parameters blood flow (BF), blood vol-
ume (BV) and mean transit time (MTT) were determined using 
a commercially available computer workstation with dedicated 
perfusion evaluation software (Syngo Volume Perfusion CT 
Neuro, Siemens, Forchheim, Germany). The processing thresh-
olds were 0 HU and 150 HU. The window width and center for 
reference vessel input were set to 300 HU and 150 HU, respec-
tively. BF, BV and MTT color-coded maps were generated with 
a sequential two-compartment model (Figure 1). BF is defined 
as the amount of blood flowing through 100 mL of prostate tis-
sue within one minute, MTT as the average time of contrast 
agent residence within the prostate tissue, and BV as the amount 
of blood within 100 mL of prostate tissue. For every patient, an 
individual arterial input fraction was determined by placing an 
analytic region of interest (ROI) into the external iliac artery to 
achieve a time attenuation curve (TAC), assuming that the TACs 
derived from internal and external iliac arteries were similar. 
Data acquisition was performed, dividing the prostate volume 
on CT into eight sectors (right/left, anterior/posterior, superior/
inferior). 
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Histopathological analysis
One expert pathologist (C.P.) performed all histopathological 
analyses. After fixation, the entire prostate was cut into hori-
zontal slices. Every slice was divided into eight sectors using a 
standardized approach in order to achieve sections correspond-
ing to the sectors on CT as mentioned above. Specimens were 
cut in 4 µm sections. For each of the eight sectors, the tumoral 
area (mm2), distance (mm) to the surgical resection margins 
and Gleason score were determined after hematoxylin-eosin 
staining. The mean intra-tumoral microvessel density (MVD; 
vessels per mm2) was assessed quantitatively after immunohis-
tochemical CD34 staining [Bond™ ready-to-use primary anti-
body CD34 (QBEnd/10)] and scanning with a Ventana™ slide 
scanner (Ventana iScan, Ventana Medical System, Roche). At 
least three photographs per section were used for visual count-
ing using Image-J (public domain, Java-based image processing 
program developed at the National Institutes of Health, U.S.). 
Main outcome measures
The primary end point of this study was to assess the association 
between CTP parameters (BF, BV, MTT) and histopathological 
parameters of PCa [tumoral area, primary and secondary Glea-
son pattern, total Gleason score, MVD] by using a sector-wise 
approach. 
Statistical analyses 
Categorical variables were presented as frequencies, quantita-
tive data as mean (standard deviation, SD) or median with range. 
Spearman’s rank correlation coefficient was used to analyze the 
correlation between sector-wise CTP values (BF, BV, MTT) and 
histopathological data [PCa area, primary and secondary Glea-
son pattern, total Gleason score, MVD]. Statistical analysis was 
conducted using IBM SPSS Statistics, Version 22.0 (IBM Corp., 
Armonk, NY, USA). All tests were two-sided, with level of sig-
nificance set to 0.05.
Results
Table 1 lists patient demographic characteristics and descriptive 
statistics. Table 2 details the values of prostate CTP parameters 
and the histopathological data obtained from surgical specimen 
analysis. 
Patient age showed a moderate correlation with MVD [ρs co-
efficients (p-values): 0.31 (0.00)], but no significant correla-
tion with tumoral area, primary (all ρs coefficients <0.2), and 
secondary Gleason patterns. Conversely, PSA showed a mod-
erate correlation with all analyzed histopathological variables 
[ρs coefficients 0.38; 0.39; 0.31 and 0.32 for MVD, tumoral 
area, primary and secondary Gleason patterns, respectively, all 
p<0.01]. 
The relationship between CTP parameters and histopathologi-
cal parameters is shown in Table 3. BF correlated weakly with 
the tumoral area [ρs coefficient (p-value): 0.25 (0.00)] and with 
MVD [0.23 (0.00)]. BV and MTT were weakly correlated with 
total Gleason score [0.22 (0.00); 0.25 (0.00), respectively]. No 
valuable correlation was found between CTP parameters and 
primary and secondary Gleason patterns. 
Discussion
Today, multiparametric MRI including perfusion is the rec-
ommended technique for the non-invasive assessment of PCa. 
However, some patients have contraindications to MRI, and not 
all institutions do have access to an MRI scanner. These are se-
lected disease states where CTP imaging might play a clinical 
role. Besides, CTP imaging is performed much faster than MRI, 
its application is more convenient for the patient, and can easily 
be combined with an abdominal staging CT as part of the same 
Figure 1. a-c. Computed tomography (CT)-perfusion imaging of one patient with prostate cancer, Gleason score 7 (3 + 4). (a) Co-
lour-coded map of perfusion parameter blood flow (BF) (28.5 mL/100 mL min-1; scale 0-40); (b) blood volume (BV) (4.1 mL/100 
mL; scale 0-15) and (c) mean transit time (MTT) (8.1 seconds, scale 0-40)
a b c
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examination, taking only 60 sec of extra time. CTP also allows 
for a direct quantification of parameters, unlike MRI. These 
characteristics render it a possible alternative for PCa patients, 
in cases where MRI cannot be performed.
Experimental work has also shown the usefulness of CTP for 
response assessment to radiotherapy and anti-angiogenic drugs.
[14,15] One inherent drawback of CTP is the additional radiation 
burden delivered to the patient, requiring a well-considered 
weighing of potential benefits of cancer characterization. It 
should however be noted that the prostate-though being the most 
sensitive organ within the field - in any way will undergo organ-
destructive treatment, be it by radiotherapy or by prostatectomy. 
In our study, the mean effective radiation dose to each individual 
was 25.6 mSv, which is within the range of current oncological 
perfusion studies.[16]
Main methodological limitations of CTP of the prostate are 
related to poor anatomical intraprostatic detail, its inability 
both to detect small tumors, and also to assess extracapsular 
extension of the disease. A recent en-bloc approach has shown 
that patients with high-grade and intermediate-grade PCa can 
be more precisely differentiated with CTP rather than with bi-
opsy.[11] However, a more comprehensive approach is desired 
that could potentially locate and characterize the tumor within 
the prostate. Thus we investigated CTP using a sector-wise ap-
proach. 
Microvessel density serves as a marker of PCa-associated an-
giogenesis.[17,18] Studies have shown that MVD is higher in PCa 
than in benign prostate tissue.[19,20] Yeung et al.[21] investigated 
the relation between MVD and PCa in vitro perfusion analyzed 
with micro-CT. Vessels in malignant regions were tiny and did 
not have an apparent lumen. This suggests that - although MVD 
can be considered a marker of neoangiogenesis from a patho-
logical point of view, however from a functional point of view 
MVD may not be linearly associated with perfusion, due to the 
potential presence of functionally non- patent vessels. The situ-
ation might be different under in vivo conditions. The in vivo 
use of CTP is based on the rationale that tumor angiogenesis is 
essential for cancer growth and CTP parameters are indirectly 
related to the micro-anatomical changes that characterize this 
process.[4] 
Ives et al.[10] evaluated ten subjects with CTP using a 16-slice 
scanner before RP. Prostate specimens were divided into 6 sec-
tors. A significant correlation between the area of maximum CT 
perfusion and PCa location was present only in the 2 subjects 
with the highest Gleason scores (8 and 10) and the highest tu-
mor volume (≥50% in ≥1 sextant region). Besides the small 
Table 1. Demographic and clinical data (n=51)
 Median  Range
Age (years) 65  49-73
Δt CT-RP (days) 62  10-145
 Mean (SD) 
PSA (ng/mL) 12 (15) 
 No.  Frequency (%)
Surgical approach  
RRP 9 18
RARP 42 82
Pathologic stage 
T2a 2 3.9
T2c 40 78.4
T3a 5 9.8
T3b 4 7.8
Δt CT-RP, time interval between computed tomography (CT) and radical 
prostatectomy (RP); PSA: prostate specific antigen; RRP: retropubic radical 
prostatectomy; RARP: robot-assisted radical prostatectomy; SD: standard deviation.
Table 3. Correlation coefficient of CT-perfusion and 
histopathologic parameters of prostate (n=408 sectors)
 BF BV MTT 
 ρs (p) ρs (p) ρs (p)
PCa area 0.25 (0.00) 0.16 (0.00) 0.03 (0.6)
Primary Gleason pattern 0.10 (0.09) 0.19 (0.00) 0.19 (0.00)
Secondary Gleason pattern 0.10 (0.11) 0.16 (0.07) 0.22 (0.06)
Total Gleason score  0.12 (0.05) 0.22 (0.00) 0.25 (0.00)
MVD  0.23 (0.00) 0.16 (0.00) 0.09 (0.14)
BF: blood flow; BV: blood volume; MTT: mean transit time; MVD: microvessel density; 
PCa: prostate cancer; ρs: Spearman's rho correlation coefficients.
Table 2. Prostate parameters (n=408 sectors) 
CT-perfusion  Mean (SD) 
BF (mL/100 mL x min-1) 39.5 (18.0) 
BV (mL/100 mL) 5.1 (2.9) 
MTT (s) 9.4 (7.1) 
Histopathology Median Range
PCa area (mm2) 15.2 0.3-559.1
Primary Gleason pattern 3  3-4
Secondary Gleason pattern 3 3-5
 Mean (SD) 
MVD (n/mm2) 148.9 (61.9) 
BF: blood flow; BV: blood volume; MTT: mean transit time; MVD: microvessel 
density; PCa: prostate cancer; SD: standard deviation.
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number of patients, their study was limited mainly by a differ-
ent CTP protocol, and technical factors due to their currently 
outdated scanner type, such as artifacts from pelvic bones, low 
temporal resolution, and limited axial coverage. Osimani et al.[9] 
performed CTP in twenty-two patients on a 64-slice scanner, 
with histolopathology as standard of reference. They reported 
a significant correlation between BV and MVD (coefficient 
0.6), which was not observed in our study. Luczynska et al.[22] 
reported a weak positive correlation between CTP-derived BV 
and MVD (correlation coefficient 0.20) in 110 PCa patients us-
ing a 16-slice scanner. In our study we found a correlation of 
MVD only with BF, but not with BV. Differences might be due 
the sector-wise approach, which might weaken such a potential 
relationship. 
Besides, the CD34 staining for MVD analysis might be inferior 
to CD31 staining, but it was used in ours as well as in the other 
studies mentioned above.[9,22] Notably, our findings for BV are 
similar to results of MRI studies where this perfusion param-
eter does not consistently correlate with MVD.[23,24] In line with 
Osimani et al.[9] we observed no correlation with MVD, while 
Luczynska et al.[22] reported a weak but positive correlation. The 
correlation we found between MVD and BF might reflect in-
creased vascularity of PCa tissue. This is further supported by 
the fact that MVD correlated with the size of tumor area in our 
study, which is probably due to a linear growth of vessels with 
the dimensional development of tumors.[25]
We also investigated the association between CTP parameters 
and Gleason grading. Luczynska et al.[26] analyzed only the pe-
ripheral zone, with periurethral tissue and the hyperplastic tran-
sition zone being excluded. They found higher BF and BV in 
high-grade PCa (Gleason score >7) rather than in intermediate-
(Gleason score=7) and low-grade (Gleason score <7) tumors. 
Similar results were found recently by Huellner et al.[11] using an 
en-bloc approach. In our study, in which we used a sector-wise 
approach, we have found correlation between Gleason score and 
BV but not with BF. BV is consistently reported to be associated 
with PCA grading and/or vascularity in different study popula-
tions and in CTP studies using different technical approaches (9, 
11, 22, 26 and present study). These results raise the question for 
a potential role of BV for non-invasive PCa characterization via 
determining tumor aggressiveness.
One strength of our study is the use of a sector-wise approach. 
This method might be more appropriate than more complex 
methods that are potentially subject to the typically diffuse na-
ture of PCa and to potential shortcomings of millimeter-wise 
comparisons. On the other hand, it might also be more appropri-
ate to use than more coarse methods, which despite being fast 
processing and user-friendly, might not appreciate smaller le-
sions well enough.[9,11]
Our study has several limitations. First, the retrospective matching 
of CT slices and histopathologic sections is prone to misregistra-
tion to some extent. However, we tried to minimize this potential 
error by careful and consensual matching of the respective slices 
and sections. Besides, the usually diffuse nature of PCa likely foils 
any attempt of true coregistration. Second, we did not account for 
coexisting prostatic pathology, such as BPH, fibrosis and inflam-
mation. However, this was not also the goal of our study, and no 
cut-off values of CTP parameters exist for the differentiation of 
these conditions. Third, the time interval between CTP scan and 
prostatectomy may have influenced the relationship of CTP param-
eters and histopathological parameters. However, PCa is known to 
be a slowly growing inert tumor, and thereby such bias is not very 
likely. Lastly, technical limitations and inter -reader variability may 
affect the reproducibility and validity of CTP analysis; however our 
study was conducted according to recent guidelines and our rather 
lengthy scanning protocol facilitates a high reproducibility.[2,27,28] 
Our study is the first CTP study to analyze prostate cancer us-
ing a sector-wise approach. Blood flow correlates both with tu-
moral area and MVD, whereas blood volume correlates with the 
Gleason score. These results suggest that a sectoral analysis is 
suitable for the non-invasive characterization of PCa with CTP. 
There is still a need for further studies to better define potential 
clinical implications of this technique. 
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